Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.

Harris KB, Nealy KL, Jackson DJ, Thornton PL.

J Pharm Pract. 2012 Jun;25(3):310-8. doi: 10.1177/0897190012442061. Epub 2012 May 1. Review.

PMID:
22550161
2.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.

Clin Ther. 2012 Mar;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. Review.

PMID:
22440513
3.

Denosumab update.

Lewiecki EM.

Curr Opin Rheumatol. 2009 Jul;21(4):369-73. doi: 10.1097/BOR.0b013e32832ca41c. Review.

PMID:
19424068
4.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial.

N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.

5.

[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].

Varenna M, Gatti D.

Reumatismo. 2010 Jul-Sep;62(3):163-71. Review. Italian.

6.

Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.

Sutton EE, Riche DM.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1000-9. doi: 10.1345/aph.1Q543. Epub 2012 Jul 25. Review.

PMID:
22837347
7.

[Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].

Bruhn C.

Med Monatsschr Pharm. 2010 Oct;33(10):370-5. Review. German.

PMID:
21072910
8.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Wensel TM, Iranikhah MM, Wilborn TW.

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510. Review.

PMID:
21923432
9.

Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.

Josse R, Khan A, Ngui D, Shapiro M.

Curr Med Res Opin. 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Epub 2013 Jan 25. Review. Erratum in: Curr Med Res Opin. 2013 Sep;29(9):1211.

PMID:
23297819
10.

Denosumab: anti-RANKL antibody.

Miller PD.

Curr Osteoporos Rep. 2009 Mar;7(1):18-22. Review.

PMID:
19239825
11.

Denosumab for treatment of postmenopausal osteoporosis.

Chitre M, Shechter D, Grauer A.

Am J Health Syst Pharm. 2011 Aug 1;68(15):1409-18. doi: 10.2146/ajhp100493. Review.

PMID:
21785030
12.

Denosumab: a review of its use in postmenopausal women with osteoporosis.

Scott LJ.

Drugs Aging. 2014 Jul;31(7):555-76. doi: 10.1007/s40266-014-0191-3. Review.

PMID:
24935243
13.

Treatment of osteoporosis with denosumab.

Lewiecki EM.

Maturitas. 2010 Jun;66(2):182-6. doi: 10.1016/j.maturitas.2010.02.008. Epub 2010 Mar 16. Review.

PMID:
20236778
14.

Denosumab: What's new?

Bogado CE, Zanchetta MB, Boailchuk JA, Massari FE, Zanchetta JR.

Curr Osteoporos Rep. 2011 Mar;9(1):12-9. doi: 10.1007/s11914-010-0040-1. Review.

PMID:
21132405
15.

Denosumab: recent update in postmenopausal osteoporosis.

Silva I, Branco JC.

Acta Reumatol Port. 2012 Oct-Dec;37(4):302-13. Review.

16.

Denosumab in postmenopausal women with low bone mineral density.

McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group.

N Engl J Med. 2006 Feb 23;354(8):821-31.

17.

[Denosumab for treatment of postmenopausal osteoporosis].

Syversen U, Halse JI, Geisler J, Eriksen EF.

Tidsskr Nor Laegeforen. 2011 Oct 4;131(19):1893-6. doi: 10.4045/tidsskr.10.1116. Review. Norwegian.

18.

Spotlight on denosumab in postmenopausal osteoporosis.

Moen MD, Keam SJ.

BioDrugs. 2011 Aug 1;25(4):261-4. doi: 10.2165/11207100-000000000-00000.

PMID:
21815702
19.

Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.

Bridgeman MB, Pathak R.

Clin Ther. 2011 Nov;33(11):1547-59. doi: 10.1016/j.clinthera.2011.10.008. Review.

PMID:
22108301
20.

RANK ligand inhibition with denosumab for the management of osteoporosis.

Lewiecki EM.

Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. Review.

PMID:
16989586

Supplemental Content

Support Center